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ABSTRACT
RNAinterference(RNAi)isaprocessinwhichdouble-
strand RNA (dsRNA) directs the specific degradation
of a corresponding target mRNA. The mediators of
this process are small dsRNAs, of  21 bp in length,
called small interfering RNAs (siRNAs). siRNAs,
which can be prepared in vitro in a number of ways
and then transfected into cells, can direct the degra-
dation of corresponding mRNAs inside these cells.
Hence, siRNAs represent a powerful tool for studying
gene functions, as well as having the potential of
being highly specific pharmaceutical agents. Some
limitations in using this technology exist because
the preparation of siRNA in vitro and screening for
siRNAs efficient in RNAi can be expensive and time-
consuming processes. Here, we demonstrate that
customoligonucleotidearrayscanbeefficientlyused
for the preparation of defined mixtures of siRNAs for
the silencing of exogenous and endogenous genes.
The method is fast, inexpensive, does not require
siRNA optimization and has a number of advantages
over methods utilizing enzymatic preparation of
siRNAs by digestion of longer dsRNAs, as well as
methods based on chemical synthesis of individual
siRNAs or their DNA templates.
INTRODUCTION
The phenomenon of RNA interference (RNAi) (1), demon-
strated in a plethora of organisms and cell types (1–8), has
been extensively used for the speciﬁc silencing of different
genes. Small interfering RNAs (siRNAs) are mediators of this
process (9–14) and can be prepared in vitro in a number of
ways to be used for RNAi.
Individual siRNAs can be chemically synthesized (11) or
transcribed from short DNA templates containing an RNA
polymerase promoter (15). Chemical synthesis of RNA is
still a very expensive procedure. The efﬁciencies of different
siRNAs for RNAi may differ signiﬁcantly, and at present
there is no way to predict their individual relative potentials.
Screening for the most efﬁcient siRNAs using cell cultures is a
laborious and expensive procedure. In addition, mutations in
a gene target site may affect the efﬁcacy of RNAi (16–18).
Therefore, several methods based on the use of siRNA
mixtures, which may contain a particular efﬁcient siRNA
(or several), have been developed. These include the prepara-
tion of siRNA mixtures using RNase III (19) or Dicer (20)
enzymes to digest longer double-strand RNAs (dsRNAs). The
short RNAs produced as a result of these digestions have been
found to be efﬁcient in RNAi.
The disadvantage of these digestive approaches, however,
is in their potential for non-speciﬁc effects. If a randomly
chopped long dsRNA contains areas of homology to other
genes, or splice variants of the same gene, the expression of
these genes might also be inhibited by cognate siRNAs. In
addition, obtaining long dsRNAs also adds to the total cost of,
and time required for, these procedures.
It would be more advantageous to use deﬁned mixtures
of siRNAs, complex enough to inhibit the desired gene
with high probability, but devoid of any siRNAs with
unwanted homologies. Besides creating higher target speciﬁ-
city, the use of such mixtures would also alleviate the need to
screen for individually active compounds. These mixtures can
be created by synthesizing and mixing several siRNAs, pre-
pared by RNA transcription from corresponding DNA oligo-
nucleotide templates. The potential utility of this approach
could be limited by the price of these mixtures, which, if
prepared by conventional oligonucleotide synthesis, would
be proportional to the number of DNA templates required.
Here, we describe a simple, fast and inexpensive method
for the preparation of soluble DNA oligonucleotide mixtures
using custom oligonucleotide arrays. Arrays of a thousand dif-
*To whom correspondence should be addressed at Seattle Biomedical Research Institute, 307 Westlake Avenue N, Suite 500, Seattle, WA 98109-5219, USA.
Tel: +1 206 256 7447; Fax: +1 206 256 7229; Email: andrew.oleinikov@sbri.org
Present addresses:
Jun Zhao, Aaken Laboratories, Inc., 227777 County Road 102, Woodland, CA 95695, USA
Matthew D. Gray, MDG Associates, Inc., 3727 SW Elmgrove Street, Seattle, WA 98126-3418, USA
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 10 e92
doi:10.1093/nar/gni091e92 Nucleic Acids Research, 2005, Vol. 33, No. 10 PAGE 2 OF 6ferent oligonucleotides can be prepared in 24–48 h using
electrochemical synthesis on the surface of a single semi-
conductor microchip (21). Here, we demonstrate that siRNA
pools,preparedusingthesearray-derivedDNAoligonucleotide
mixtures, is an inexpensive and efﬁcient tool for the inhibition
of exogenous as well as endogenous genes in cell cultures.
MATERIALS AND METHODS
Preparation of oligonucleotide arrays
Oligonucleotide arrays were synthesized in the membrane
on CombiMatrix semiconductor microchips (CombiMatrix
Corp., Mukilteo, WA) as described previously (21). All arrays
contained 60 different oligonucleotides, each containing (from
50 end) 20mer T7 RNA polymerase promoter, 21 bases of the
corresponding gene (+ or – chain) followed by a TT dinucleo-
tide and 30-ﬂanking sequence, and attached to the chip mem-
brane at its 30 end (Figure 1). 30-Flanking sequences were as
follows: for control SARS siRNA array 50-CCTACGACT-
CATTCCTACCAT-30, for enhanced green ﬂuorescent protein
(EGFP) siRNA array 50-GAGACGACTCCTAATCGAAT-30
and for Raf-1 siRNA array 50-CGTAAGACTCAGCGTGA-
TGGT-30. Each ﬂanking sequence contains a recognition site
forMlyI restrictionendonuclease with its cut sitelocated atthe
50 endoftheﬂankingsequence. Underlinedﬂankingsequences
are complementary to the corresponding PCR primers used
(Primer 2 in Figure 1A and B).
Preparation of the mixtures of soluble siRNA using
microarrays
ForPCR,semiconductorchipswerebrokenintoseveralpieces,
and chip oligonucleotides were ampliﬁed in 50 ml mixtures
using two primers. One primer was an oligonucleotide resem-
bling T7 RNA polymerase promoter 50-TAATACGACTCAC-
TATAGGG-30, the other primer was complementary to the
ﬂanking sequence, as described above. Thirty cycles of PCR
were as follows: 95 C for30 s, 56 Cfor30 s,72 Cfor 45 s and
one cycle at 72 C for 7 min. After PCR, reaction mixtures,
without puriﬁcation, were digested with MlyI for at least 2 h at
37 C. After digestion, soluble double-strand oligonucleotides
produced from different pieces of the chip were combined
and puriﬁed by Qiagen gel-puriﬁcation kit (without gel elec-
trophoresis) into 100 ml of elution buffer. Transcription and
annealing was performed using24 ml of mixed oligonucleotide
templates in 80 ml of reaction volume using the Silencer 
siRNA construction kit (Ambion, Austin, TX). After an over-
night incubation at 37 C, dsRNA samples were treated with
DNase and single-strand-speciﬁc RNase (from the same kit),
and puriﬁed, using ﬁlter cartridges included in the kit, into
100 ml of nuclease-free water. Concentration was measured
by absorbance at 260 nm, and yields were typically between
60 and 90 mM.
Cloning and sequencing of DNA oligonucleotides
prepared by PCR from on-chip synthesized
oligonucleotides
Double-strand DNA (dsDNA) oligonucleotides, ampliﬁed
by PCR as described above, were cloned into the pCR4-
TOPO*TA vector (Invitrogen). DNA was puriﬁed using
Wizard plasmid puriﬁcation kit (Promega) and sequenced at
Davis Sequencing (Davis, CA).
Gel electrophoresis of DNA and siRNA
Samples were separated in precast 4% agarose gels (contain-
ing ethidium bromide) in TBE buffer (Cambrex BioScience
Rockland, Inc., Rockland, ME). A total of 10 bp DNA Step
Ladder from Promega was used in these experiments as
molecular weight marker.
Cell culture and transient transfections
HeLa cells were grown in EME medium (ATCC) supplemen-
tedwith10%fetalcalfserum,1mM L-glutamineand100U/ml
of penicillin–streptomycin at 37 C, with 5% CO2. Cells were
seeded in six-well tissue culture plates and grown to 50–70%
conﬂuency for transient transfection experiments. For asses-
sing the effect of the EGFP siRNA pool on exogenous EGFP
expression, a series of concentrations (0, 12.5, 25 and 50 nM)
of EGFP siRNA or control SARS siRNA pools were each
co-transfected with 0.7 mg/well of the pEGFP-N1 expression
vector (Clontech) and 0.5 mg/well of pSEAP reporter vector
(Clontech), which was used as a control for transfection
efﬁciency. For examining endogenous c-raf gene silencing,
a similar series of concentrations of human Raf-1 siRNAs
or control SARS siRNA pools were each co-transfected
with 0.7 mg/well of the pEGFP-N1 vector (Clontech), which
was used as a control for transfection efﬁciency. Transfection
experiments were performed using LipofectAMINE 200
Reagent (Invitrogen) according to the manufacturer’s instruc-
tions. The functional effects on expression of target genes
were measured by ﬂuorescence microscopy using ﬂuorescein
Figure 1. (A) General scheme for the preparation of siRNA mixtures using custom oligonucleotide arrays. E1 and E2 are electrodes, over which different
oligonucleotides 1 and 2 are synthesized. Three sets of siRNA were designed. A control set was composed using information on SARS coronovirus CUHK-
W1 (accession no. AY278554) and contained 30 different double-strand siRNAs cognate to viral mRNA coding for RNA-dependent RNA polymerase and metal-
binding NTPase/helicase domains. To inhibit the expression of exogenous GFP, we designed 30 siRNAs covering the full sequence of its mRNA, starting from the
firstATGcodon(pEGFP-N1,accessionno.U55762)andshiftedrelativetoeachotherby21bases.ToinhibittheexpressionoftheendogenousRaf-1proto-oncogene,
we designed 30 siRNAs derived from the entire sequence of  3000 bases of the human Raf-1 mRNA (accession no. X03484) (22). The first siRNA started at base
–129 relative to the initiator ATG codon. Each 21mer oligonucleotide was separated from the next by 90 bases. All oligonucleotide sequences (sense chain) are
includedintheSupplementaryMaterial.(B)DetailedschemeforthepreparationofSARSsiRNAmixtureshowingoligonucleotidesequencesusedforpromoterand
flankingregions,andapairofinternalcomplementarychainsencodingSARSsiRNA#1asanexample.EachDNAoligonucleotidecontainedaT7RNApolymerase
promoterprecedingthespecificsiRNAtemplates.(C)DNAandRNAproductsgeneratedduringsiRNAmixturepreparation.Left:4%agarosegelanalysisofsoluble
dsDNA oligonucleotide siRNA templates prepared by PCR amplification of array oligonucleotides as shown in (A and B). PCR was performed using two primers,
commonforall the oligonucleotidessynthesizedon a particularchip.To excludethe possibilityof cross-contaminationbetweensiRNApoolsduringamplification,
different pairs of primers were used for chips designed with SARS, GFP and Raf-1 oligonucleotides. One primer, containing a T7 RNA polymerase promoter, was
commonforallsequences;theother,PCRprimer2,wasdifferentineachcase(seeMaterialsandmethods).Before:PCRproductsbeforedigestionwithMlyI(63bp);
after:PCRproductsafterdigestionwithMlyIandpurification(43bp).M:DNAoligonucleotidemarkers.Right:siRNAmixturepreparationsanalyzedby4%agarose
gel electrophoresis. The mixtures of siRNAs migrate at an approximate size of 25 bp dsDNA oligonucleotides.
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(Raf-1) after 24 h (EGFP and Raf-1) and 48 h (EGFP)
post-transfection. In each case, at least three independent
transfection experiments were performed.
Western blotting of EGFP, beta-actin and Raf-1
The expression of EGFP, beta-actin and Raf-1 proteins were
examined by western blotting. Brieﬂy, siRNA-treated cells
were lysed in cold passive lysis buffer (Promega) for 30 min
on ice. Protein concentrations in samples were measured using
Bio-Rad Protein Assay (Bio-Rad). Equal amounts of proteins
(usually 2 mg) from each sample were mixed with 2· SDS
buffer (Bio-Rad), heated at 95 C for 5 min and fractionated by
4–15% gradient SDS–PAGE. Gels were then transferred onto
Immobilon-P polyvinylene diﬂuoride membrane (Bio-Rad)
overnight at 4 C by wet transfer system (Bio-Rad). Mem-
branes were blocked in TBST (50 mM Tris–HCl, pH 7.4,
150 mM NaCl and 0.05% Tween-20) containing 10% non-
fat milk, and then probed with rabbit anti-Raf-1 antibody
(1:500; Sigma), rabbit anti-EGFP antibody (1:500; Clontech)
or mouse anti-beta-actin antibody (1:500; Sigma) in TBST
containing 1% non-fat milk for 2 h at room temperature.
Western blots to detect beta-actin and EGFP were performed
by re-probing membranes used for Raf-1 detection. After
washing three times in TBST, membranes were further incub-
ated with the appropriate anti-rabbit or anti-mouse secondary
antibodies (both from Jackson ImmunoResearch Laboratories)
conjugated to horseradish peroxidase (1:1000) for 1 h at room
temperature. Membranes were washed three times in TBST,
two times in TBS, and developed using LumiGLO chemilu-
minescent substrate kit (KPL, Gaithersburg, MD). Images
were recorded, and band intensities on western blots were
quantiﬁed, using the CCD-based FluorChem  8000 Imaging
System (Alpha Innotech Corp.).
RESULTS AND DISCUSSION
Figure 1A and B shows our scheme for the preparation of
a mixture of siRNAs using a custom DNA oligonucleotide
array. Using this scheme, we prepared three sets of siRNA
mixtures, each containing 30 double-strand siRNAs: negative
control SARS siRNAs, EGFP siRNAs and Raf-1 siRNAs. We
presumed that virally targeted SARS siRNAs would not affect
the expression of the genes, which we used to assess speciﬁc
RNAi effects, EGFP and Raf-1, and that they could be used
as negative controls in our experiments. The siRNAs designed
all had a similar structure: 21 bp corresponding to the gene
sequence and two unpaired U’s at each 30 end (Figure 1B).
Figure 1C shows agarose gel electrophoresis of oligo-
nucleotides and dsRNA samples from different steps of the
siRNA mixture preparation. After PCR, the resulting dsDNA
oligonucleotides were treated with MlyI restriction enzyme
to remove one ﬂanking sequence (on the opposite side from
T7 promoter) in order to create precise templates for transcrip-
tion (Figure 1B). Agarose gel electrophoresis (Figure 1C)
conﬁrmed both the correct size and complete digestion of
PCR fragments. To conﬁrm the diversity and the quality of
chip-derived DNA templates, PCR products were also cloned
(before digestion with MlyI enzyme) for sequencing. The
18 clones examined represented 16 different siRNA-coding
sequences, and each siRNA-coding 21mer contained 100%
correct sequence.
Transcription of the original mixture of templates produced
corresponding single-strand RNAs (ssRNAs) containing a
GG-pair at their 50 ends (as a result of T7 polymerase tran-
scription initiation), 21 bases cognate to the selected gene, and
a UU-pair at their 30 ends. All complementary chains were
synthesized together in a single reaction, and dsRNAs were
formed directly during the transcription process. No additional
melting–annealing steps were performed because the long
incubation at 37 C is sufﬁcient for the formation of dsRNAs.
Reactions were treated with DNase to remove the DNA oli-
gonucleotide templates, and with 50 single-strand-speciﬁc
RNase to remove the GG-overhanging bases from the 50
ends of dsRNAs. After puriﬁcation, the typical ﬁnal concen-
trations of the siRNA mixtures, prepared from a single micro-
chip, were  60–90 mM (or 80–120 mg total siRNA in 100 ml),
which is sufﬁcient for many cell culture experiments. It is
clear that the electrophoretic mobility of these dsRNA mix-
tures is between the 20 and 30 bp dsDNA markers (median at
25 bp), which corresponds perfectly to the expected mobility
of 21mer dsRNAs with two overhanging nucleotides at each
30 end (Figure 1C).
The functional activity of siRNAs prepared using custom
oligonucleotide arrays was tested in RNAi cell culture experi-
ments. Results of an RNAi experiment with exogenous GFP
transfected into HeLa cells together with siRNA preparations
(control SARS or EGFP siRNA) are shown in Figure 2. Trans-
fection efﬁciency was similar in different samples, based
on the activity of the co-transfected marker, secreted alkaline
phosphatase (SEAP) (data not shown). It is clear that the
expression of EGFP is signiﬁcantly reduced by treatment
with the GFP siRNA mixture but not by the control SARS
siRNA mixture. The inhibitory effect was clearly visible 24 h
Figure 2. Inhibition of EGFP expression in HeLa cells by RNAi analyzed by
fluorescence microscopy. The same microscope field is shown in white light
(all cells are visible) and fluorescence light (only cells expressing EGFP are
visible) for each sample. (A) Twenty-four hours post-transfection; (B)4 8h
post-transfection.
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and was almost complete at 50 nM (Figure 2).
Figure 3 demonstrates that our siRNA mixtures can signif-
icantly reduce the expression of endogenous Raf-1 genes.
HeLa cells were transfected with none, control (SARS) or
Raf-1 siRNA mixtures at different concentrations. pEGFP
reporter plasmid was included in the transfection mixtures
as a control for transfection efﬁciency. At the bottom of the
ﬁgure is shown western blotting data from a typical RNAi
experiment (chemiluminescence images are reversed). The
graph in this ﬁgure demonstrates the average inhibitory effect
in four independent cell-culture experiments. The effect
of Raf-1 siRNA on the level of Raf-1 protein is dose-
dependent; at a 50 nM siRNA concentration, Raf-1 expression
is inhibited by  80% compared with the 50 nM siRNA con-
trol. Since this level of inhibition is comparable with the over-
all transfection efﬁciency ( 80%, calculated by counting
EGFP-positive cells), it appears that Raf-1 expression is
almost completely inhibited in the population of successfully
transfected cells at this concentration. It is evident from wes-
tern blot control data and from a visual inspection of treated
cells that siRNA mixtures were not toxic at the concentrations
used during our experiments.
The results presented clearly demonstrate that our method
of preparing siRNA using custom DNA oligonucleotide arrays
isefﬁcient inthe production offunctionally active compounds.
The inhibitory effects of the siRNA mixtures on gene expres-
sion in this study were comparable with, or better than, those
of mixtures prepared by RNase III digestion of full-length
EGFP dsRNA (data not shown). In addition to the dimeric
dsRNA described here, siRNAs can also be designed as
hairpin loops (3). This would double the potential number
of different siRNAs that can be synthesized per chip, as
both strands of the RNA duplex are encoded within a single
oligonucleotide. Hairpin loops might also be more favorable
for very complex mixtures of siRNAs owing to their high
potential for intra-molecular double-strand formation. The
custom nature of the CombiMatrix array platform provides
for the incorporation of various elements of structural and
informatic design in generating deﬁned mixtures of siRNAs.
For example, in our design of the control SARS siRNAs,
we chose only gene fragments that contain minimal homo-
logy to published human genes in hope of minimizing non-
speciﬁc effects on cells. Hence, any potentially cross-reactive
sequences (e.g. sequences that contain homology to closely
related known targets or, perhaps, those having minimal
homology to a particular ’background’ genome) can be
excluded from a set of siRNAs in order to optimize them
for gene-speciﬁc targeting.
Different siRNA mixtures can be prepared from a single
microarray in a variety of ways, e.g. by physical breaking of
the array into individual pieces, by the use of different primers
for the ampliﬁcation of different sets of siRNA template
DNA oligonucleotides, or, in addition, by the use of different
RNA polymerase promoter sequences introduced into siRNA
template DNA oligonucleotides. The more different siRNAs,
or the more different siRNA pools, that are prepared using the
same microchip, the lower the price of each siRNA, or pool,
would be. Preparation a single pool of siRNA consisting of
30 different double-strand siRNAs by conventional transcrip-
tion methods requires sixty 29mer DNA oligonucleotides (e.g.
using Ambion’s Silencer  siRNA construction kit). Assum-
ing a lowest possible price of $0.14 per base for oligonucleo-
tides prepared in-house, the minimal total cost for these oligos
alone would be about $250. This is about twice the price
of preparing a single oligonucleotide array on the current
CombiMatrix platform, including all expenses, irrespective
of the number of different oligonucleotides made (up to
1000). Therefore, CombiMatrix oligonucleotide arrays are
cheaper than conventional methods of preparing DNA tem-
plates for siRNA transcription; depending on the number
of oligonucleotides in the mixture, or the number of
mixtures, they can be signiﬁcantly cheaper. Because semicon-
ductor devices are scalable, without price increase, the
price advantage over individually synthesized and mixed
DNA oligonucleotide templates will increase further with
the use of arrays with higher densities of different
oligonucleotides.
Although the actual data are incongruous, two types of off-
target effects have been described in the literature: (i) a non-
speciﬁc effect, which is independent of sequence homology
with a particular siRNA and (ii) a speciﬁc effect, when non-
targeted genes with partial complementarity to a particular
siRNA directed against the target gene are downregulated
(23–25). These effects can be problematic, and are complex
and not readily reproducible, because they depend upon the
particular system and target proteins that are used. In the
present study, we did not investigate whether our siRNA
mixtures would reduce potential off-target effects. This was
outside the scope of our present work as it represents a more
general issue concerning the use of RNAi technology. Never-
theless, a simple assumption suggests that by excluding
Figure 3. Inhibition of endogenous Raf-1 expression in HeLa cells by RNAi
analyzed by western blotting. Top: light intensity for each Raf-1 band was
normalizedtothebeta-actinbandinthesamelaneand,forcomparisonbetween
different experiments (4 total), these data were normalized relative to the
untreated controls (without siRNA). The differences between Raf-1 siRNA-
treatedcellsandcontrolSARSsiRNA-treatedcellswerestatisticallysignificant
at each concentration examined (P < 0.006 by paired t-test). Bottom: typical
western blotting (WB) data from a single RNAi experiment. Chemilumines-
cence images are shown in negative. None, control without siRNA; contr,
control SARS siRNA.
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prevent at least the ‘speciﬁc type’ of off-target effect.
Although this still may not remove possible non-target effects
owing to residual homologies that are potentially impossible
to avoid completely due to the enormous size and undeﬁned
nature of some genomes, the use of complex mixtures of
deﬁned siRNA molecules may also offer a unique advantage
over current methods. Because each efﬁcient siRNA has an
optimum concentration when its effect is maximal (the prac-
tical effective concentration range is 10–100 nM), if such an
siRNA molecule, homologous to an off-target gene, were pre-
sent in a deﬁned mixture, it is likely that its concentration
would be below the effective range. Thus, since a complex
mixture may include 30–50 different siRNAs at a total con-
centration of 10–100 nM, this may, theoretically, lessen the
off-target effect of that particular siRNA molecule because it
is contained within a mixture. Whether siRNA mixtures can
reduce either type of off-target effect or not will, hence, be the
focus of future research.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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